R.E.D. Laboratories was founded in 1998 to develop and commercialize the pioneering work of Dr. Robert Suhadolnik at Temple University who in 1995 discovered the presence of an abnormal protein in a subset of patients with Chronic Fatigue Syndrome (CFS). This protein is related to a normal enzyme, Ribonuclease L (RNase L), one of the interferon-inducible enzymes, which protects the body during a viral infection. An increased amount of this abnormal protein defines a clinical subset of CFS patients. In 2000 the Company started its own research and development activities on chronic immune diseases. Assay development and research programs at R.E.D. Laboratories now focus on inflammatory mechanisms, oxidative stress, intestinal dysfunctions and viral infections, all disorders that contribute to the onset and pathogenesis of diseases such as CFS, multiple sclerosis, or autoimmune diseases.
R.E.D. Laboratories facility in Zellik, Belgium:
